Printer Friendly

MEDI-PHYSICS/AMERSHAM HEALTHCARE AND ZENECA PHARMACEUTICALS SET CO-PROMOTION AGREEMENT FOR CANCER PAIN THERAPY AGENT

 ARLINGTON HEIGHTS, Ill., March 30 /PRNewswire/ -- Medi-Physics, Inc./Amersham Healthcare, the U.S. arm of Amersham International plc, and Zeneca Pharmaceuticals Group, a business unit of Zeneca Inc., today announced that their parent companies, Amersham International plc and Zeneca Limited, had reached an agreement to co-promote Metastron(R) (strontium-89 chloride injection), upon U.S. Food and Drug Administration approval for marketing. Metastron is a radiopharmaceutical treatment for relief of pain from cancer that spreads to bone.
 Clinical studies have demonstrated that a single injection of Metastron, administered as an out-patient treatment, provides significant pain relief lasting three months or more in the majority of patients. As with many of the newer innovative pharmaceuticals, Metastron has been associated with fewer side effects and equal or lower daily cost when compared to older treatments. Metastron has been approved for marketing in ten countries.
 Under the international agreement, the Zeneca sales force will also promote Metastron to urologists and medical oncologists who prescribe Zoladex(R) (goserelin acetate implant), the Zeneca hormonal treatment for advanced prostate cancer. Amersham will maintain responsibility for manufacturing and distribution of Metastron, further registration work and related clinical trials, as well as the promotion of the product to nuclear medicine, radiopharmacy and radiation oncology specialists.
 "We are pleased to be associated with a world-class company such as Zeneca," said Alan F. Herbert, president of Medi-Physics, Inc./Amersham Healthcare. "This agreement combines Zeneca's extensive experience in the oncology and urology marketplace with Amersham's successful track record for radioactive products. The melding of the resources of Zeneca and Amersham will offer physicians and cancer patients greater access to the innovative approach to pain relief afforded with Metastron."
 Many late-stage cancer patients develop bone metastases, a condition that can cause severe, unremitting pain. Metastron offers these individuals a new approach to their pain management.
 "This co-promotion agreement offers obvious synergies to both Zeneca Pharmaceuticals and Amersham," noted Robert C. Black, president of Zeneca Pharmaceuticals Group. "Metastron represents a perfect fit with the products we already provide to physicians who care for cancer patients. Our sales force is very familiar with the particular needs of these healthcare providers, and their experience and knowledge will complement Amersham's promotional efforts with the nuclear medicine and radiation oncology communities."
 Zeneca Pharmaceuticals Group (formerly ICI Pharmaceuticals Group) is ranked among the top research-based pharmaceutical companies in the U.S. The company, which comprises Zeneca Pharmaceuticals (formerly ICI Pharma) and Stuart Pharmaceuticals, is a business unit of Zeneca Inc. based in Wilmington, Delaware. Zeneca has earned a reputation as a research-intensive company dedicated to pharmaceutical discovery, development and production. Through numerous public awareness campaigns, corporate health programs, and patient assistance programs, Zeneca Pharmaceuticals Group provides health education and support services to millions of Americans. Zeneca Pharmaceuticals Group is headquartered in Wilmington, Delaware; the company's U.S. manufacturing facility is located in nearby Newark, Delaware.
 Medi-Physics, Inc./Amersham Healthcare is a major supplier to the U.S. nuclear medicine and radiation oncology communities. The company owns and operates a chain of 20 radiopharmacies in major U.S. cities, and has offices and manufacturing facilities in Arlington Heights, Illinois and South Plainfield, New Jersey.
 Metastron is among several diagnostic and therapeutic radiopharmaceuticals developed by Amersham International plc, the U.K. based health science group and world leader in the supply of advanced products and specialized technologies for use in life sciences research, health care, and industrial quality and safety assurance.
 NOTE: Metastron is the registered trademark of Amersham International, plc., and Zoladex is the registered trademark of Zeneca Limited.
 -0- 3/30/93
 /CONTACT: William A. Ehmig, vice president-professional affairs of Medi-Physics, Inc./Amersham Healthcare, 708-593-6300, ext. 244, or Joel Tau, manager-media and association relations of Zeneca Pharmaceuticals Group, 302-886-7858, or Stacey Harris of Makovsky & Company, 212-532-6300, for Amersham International, plc., and Zeneca Pharmaceuticals Group/


CO: Medi-Physics Inc.; Amersham Healthcare; Zeneca Pharmaceuticals ST: Illinois IN: MTC SU: JVN

TM -- NY008 -- 0850 03/30/93 08:00 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 30, 1993
Words:657
Previous Article:FINGERMATRIX FILES PRELIMINARY PROXY STATEMENT
Next Article:BED BATH & BEYOND INC. REPORTS FOURTH QUARTER AND YEAR ENDED FEBRUARY 28, 1993 EARNINGS AND MARCH 1993 SALES
Topics:


Related Articles
MEDIMMUNE ENTERS DISTRIBUTION AGREEMENT FOR CYTOGAM IN EASTERN EUROPE AND FORMER U.S.S.R.
MALLINCKRODT MEDICAL, INC. ESTABLISHES NATIONAL DISTRIBUTION OF ITS PROPRIETARY PRODUCTS WITH MEDI+PHYSICS, INC.
INCYTE SIGNS EIGHTH GENOMIC DATABASE AGREEMENT WITH ZENECA
ZENECA Diagnostics and OncorMed Join Forces to Develop and Commercialize New Cancer Tests
Medi-Ject Enters Into Feasibility Agreement with SmithKline Beecham
Mallinckrodt, Medi-Physics Reach Agreement on Myoview(TM) Heart Imaging Agent
UroCor to Co-Promote Two Zeneca Prostate Cancer Drugs
Zeneca Announces Co-Promotion Agreement With UroCor to Enhance Reach to U.S. Urology Community
UroCor Completes National Sales Force Expansion & Training for Zeneca Co-Promotion
Nycomed Amersham Imaging and Health Services Corporation of America (HSCA) Announce Contract Extension.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters